

1 Forest Parkway Shelton, CT 06484 800-328-2666 203-926-7100

LOWER GI TEST REQUISITION

Labeton p specially lesting group									
ACCOUNT INFORMATION		PATIEN	IT INFORM	MATION					
ACCOUNT NO. TELEPHONE NO.						_			
			CHART N		RED	-	PATIENT	D O R	
ACCOUNT NAME AND ADDRESS				CHART NOW	DLK		FAILENT	Б.О.В.	
ACCOUNT NAME AND ADDRESS									
			PATIENT L	AST NAME		FIRST NA	ME M.	l.	
			STREET AD	DRESS					
REQUESTING PHYSICIAN (PLEASE PRINT) PHYSICIAN/AUTHORIZED SIGNATURE			CITY	- I			STATE ZIP	CODE	
REQUESTING TITTSICIAN (LEASE TRINT)	THISICIAN (LEASE) NINT)			SEX M				=	
REQUESTING PHYSICIAN NPI REFERRING PHYSICIAN			RACE		MRN / PATIE	ENT ID #	PATIENT	TELEPHONE NO.	
BILLING INFORMATION									
	Diagnosis/Signs/Symptoms in ICD-CM format	in effect at D	ate of Service	e (Highest Specific	ity Required)	REQUIRED			
BILL: ☐ PRACTICE/FACILITY ☐ PATIENT ☐ MEDICARE ☐ MEDICAID ☐ IN						ICD-CM CO	DDE(S):		
POLICY/ID# GROUP #						GROUP #			
INSURANCE CARRIER									
CITY	STATE ZIP		_ CITY			STATE	ZIP		
PATIENT HOSPITAL STATUS 🗌 INF	Patient 🗌 outpatient 🗌 non-pati	ENT		d's name			_ INSURED'S DOB		
					HP TO INSUR	ED: L SP	ouse 🗌 child [OTHER	
CLINICAL DATA (Checl		ENDO	SCOPIC	CODES					
Bleeding	Family history of cancer			plicable numl NOT CIRCLE			onding biopsy spe	cimen in the next	
Diarrhea (bloody)	(type)	1 Erosio		NOT CIRCLE 6 Norma			1 Stricture		
☐ Diarrhea (watery)	Personal history of cancer	2 Erythe	ema	7 Polyp			2 Ulcer		
_	,	3 Grani 4 Mass	ilarity	8 Polypo 9 Pseudo	osis omembrane				
☐ Weight loss	(type)	5 Nodu	larity						
☐ Pain	Personal history of Colon polyps								
Heme positive stool	Personal history of idiopathic inflammatory bowel disease	BIOPS	Y DATA						
Theme positive stool	illiallillatory bower disease			ross and Micros	•				
				ferred slides (Se					
		Const	iitation <i>t</i> Kei		equiring slide SITE (Check		pathology report) DESCRIPTOR	ENDOSCOPIC	
SPECIAL INDICATIONS				ي الملكو				FINDINGS	
] eum eo Ceca Valve Ascendin.	Thepatic Flexure Transverse Descentic	<u></u>	.s one)	(See codes above)	
☐ Colitis surveillance colonoscopy	☐ Rule out idiopathic inflammatory bowel disease	SPECI	MEN	n Ce _C um	Patic, Psver, Pnic f	oid Doid tum Stam	Proximal Mid Distal	I	
Polyp/neoplasm	Rule out Crohn's	#	From] 74. 58. 58.	Sign Rec Ana	Proxim, Mid Distal		
surveillance colonoscopy	Rule out ulcerative colitis		cm					,	
Rule out viral inclusions	Rule out dysplasia		cm						
Rule out parasites	Rule out malignancy		cm						
Other:		—— –	cm						
SPECIMEN COLLECTION			cm						
COLLECTION DATE://	/		cm						
☐ Biopsy ☐ Brush	hing Polypectomy		cm					- ,	
☐ Washing ☐ Othe	r:	CYTO	.OGY D		CITE (Charal		DECCRIPTOR	ENDOCCORIC	
LYNCH SYNDROME (Comple	ete Biopsy Data Section)				SITE (Check	,	(Check only	ENDOSCOPIC FINDINGS	
☐ Histology† (Gross & Microscopic	Exam) w/Reflex to Lynch Syndrome			λ_{ah}	lekure s	sante Se	one)	(See codes above)	
	n* if meets Revised Bethesda criteria •	SPECI	MEN	r Geg,	"din Itic F Svers, Pic Fi	`endi; 'oid um	limal le		
☐ Histology† (Gross & Microscopic Comprehensive Tumor Evaluation	n* if carcinoma	#	From	lleum Neo _{Cecal V} ahe Cecum Asces, L	- nding Hepatic Flexure Transverse Splenic Flex] Descending] Sigmoid] Rectum	Proximal Mid Distal		
	IS2 by IHC and/or MSI by PCR. If MLH1		cm					,	
is deficient, reflex to BRAF Gene N Promoter Methylation#	Mutation; if negative, reflex to MLH1		cm					·	
♦ Revised Bethesda guidelines for	testing colorectal tumors for MSI:	<u> </u>	cm					,	
Colorectal cancer diagnosed in	a patient who is <50 years of age, or	OTHE	R TESTS						
Colorectal cancer with the MSI- who is <60 years of age	-H histology diagnosed in a patient								
	by LabCara/s Integrated Oncology division	I							

When ordering tests for which Medicare or Medicaid reimbursements will be sought, physicians should order only those tests that are medically necessary for the diagnosis or treatment of the patient. #Separately billable stains may be added by pathologist when medically necessary to render a diagnosis.

Test Combination/Panel Policy

LabCorp's policy is to provide physicians, in each instance, with the flexibility to choose appropriate tests to assure that the convenience of ordering test combinations/panels does not distance physicians who wish to order a test combination/profile from making deliberate decisions regarding which tests are truly medically necessary. All the tests offered in test combinations/panels may be ordered individually using the LabCorp request form. LabCorp encourages clients to contact their local LabCorp representative or LabCorp location if the testing configurations shown here do not meet individual needs for any reason, or if some other combination of procedures is desired.

In an effort to keep our clients fully informed of the content, charges and coding of its test combinations/panels when billed to Medicare, we periodically send notices concerning customized test combinations/panels, as well as information regarding patient fees for all LabCorp services. We also welcome the opportunity to provide, on request, additional information in connection with our testing services and the manner in which they are billed to physicians, health care plans, and patients.

The CPT code(s) listed are in accordance with the current edition of *Current Procedural Terminology*, a publication of the American Medical Association. CPT codes are provided for the convenience of our clients; however, correct coding often varies from one carrier to another. Consequently, the codes presented here are intended as general guidelines and should not be used without confirming with the applicable payor that their use is appropriate in each case. All laboratory procedures will be billed to third-party carriers (including Medicare and Medicaid) at fees billed to patients and in accordance with the specific CPT coding required by the carrier. Microbiology CPT code(s) for additional procedures such as susceptibility testing, identification, serotyping, etc. will be billed in addition to the primary codes when appropriate. LabCorp will process the specimen for a Microbiology test based on source.

Determining Necessity of Advance Beneficiary Notice of Noncoverage (ABN) Completion*

- 1. **Diagnose.** Determine your patient's diagnosis.
- 2. **Document.** Write the diagnosis code(s) on the front of this requisition.
- 3. **Verify.** Determine if the laboratory test(s) ordered for the patient is subject to Local Coverage Determination or National Coverage Determination. This information can be located in the policies published by your Medicare Administrative Contractor (MAC), CMS, or www.LabCorp.com/MedicareMedicalNecessity.
- 4. **Review.** If the diagnosis code for your patient <u>does not</u> meet the medical necessity requirements set forth by Medicare or the test(s) is being performed more frequently than Medicare allows, an ABN should be completed.

*An ABN should be completed for all tests that are considered investigational (experimental or for research use) by Medicare.

How to Complete an Advance Beneficiary Notice of Noncoverage (ABN)

Medicare is very specific in requiring that all of the information included on the ABN be completed. Additionally, LabCorp requests that the specimen number or bar code label be included on the form. To be valid an ABN must:

- 1. Be executed on the CMS approved ABN form (CMS-R-131)
- 2. Identify the Medicare Part B Beneficiary, using the name as it appears on the patient's red, white and blue Medicare card
- 3. Indicate the test(s)/procedure(s) which may be denied within the relevant reason column
- 4. Include an estimated cost for the test(s)/procedure(s) subject to the ABN
- 5. Have 'Option 1', 'Option 2', or 'Option 3' designated by the beneficiary
- 6. Be signed and dated by the beneficiary or his/her representative prior to the service being rendered

Symbols used to designate Medicare medical review as of 10/01/2018

- @ = Subject to Medicare medical necessity guidelines.
- % = Subject to Medicare frequency guidelines.
- # = Medicare deems investigational. Medicare does not pay for services it deems investigational.

